Literature DB >> 12134052

Inserting a nuclear targeting signal into a replication-competent Moloney murine leukemia virus affects viral export and is not sufficient for cell cycle-independent infection.

Jennifer A Seamon1, Kathryn S Jones, Christina Miller, Monica J Roth.   

Abstract

The effects of inserting reported nuclear localization signals (NLSs) into the Moloney murine leukemia virus (Mo-MuLV) integrase (IN) protein, within a replication-competent viral construct, were studied. In contrast to the virus harboring IN fused to the simian virus 40 (SV40) large T antigen NLS (SV40 NLS) (J. A. Seamon, M. Adams, S. Sengupta, and M. J. Roth, Virology 274:412-419, 2000), a codon-modified SV40 NLS was stably expressed during viral propagation. Incorporation of the codon-modified SV40 NLS into IN, however, altered the packaging of the Gag-Pol precursor in the virus; viral particles contained decreased levels of reverse transcriptase (RT) and IN. In addition, the virus showed delayed kinetics of viral DNA synthesis upon infection. A panel of infectious MuLVs containing alternative IN-NLS fusions was generated and assayed for cell cycle-independent infection. Viral infection with the NLS-tagged proteins, however, remained dependent on passage of the cells through mitosis. This finding has direct implications for engineering murine-based retroviral vectors for gene therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12134052      PMCID: PMC155121          DOI: 10.1128/jvi.76.16.8475-8484.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

1.  A gene therapy approach for treating T-cell-mediated autoimmune diseases.

Authors:  C Chen; A Rivera; N Ron; J P Dougherty; Y Ron
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

2.  Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1.

Authors:  A Fassati; S P Goff
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Two nuclear localization signals in the HIV-1 matrix protein regulate nuclear import of the HIV-1 pre-integration complex.

Authors:  O K Haffar; S Popov; L Dubrovsky; I Agostini; H Tang; T Pushkarsky; S G Nadler; M Bukrinsky
Journal:  J Mol Biol       Date:  2000-06-02       Impact factor: 5.469

4.  Replication of phenotypically mixed human immunodeficiency virus type 1 virions containing catalytically active and catalytically inactive reverse transcriptase.

Authors:  J G Julias; A L Ferris; P L Boyer; S H Hughes
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  HIV-1 infection requires a functional integrase NLS.

Authors:  M Bouyac-Bertoia; J D Dvorin; R A Fouchier; Y Jenkins; B E Meyer; L I Wu; M Emerman; M H Malim
Journal:  Mol Cell       Date:  2001-05       Impact factor: 17.970

6.  Nucleocytoplasmic shuttling by human immunodeficiency virus type 1 Vpr.

Authors:  M P Sherman; C M de Noronha; M I Heusch; S Greene; W C Greene
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

7.  Maintenance of the Gag/Gag-Pol ratio is important for human immunodeficiency virus type 1 RNA dimerization and viral infectivity.

Authors:  M Shehu-Xhilaga; S M Crowe; J Mak
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

8.  Differential effects of C-terminal molecular tagged integrase on replication competent moloney murine leukemia virus.

Authors:  J A Seamon; M Adams; S Sengupta; M J Roth
Journal:  Virology       Date:  2000-09-01       Impact factor: 3.616

9.  Genetic analysis of the human immunodeficiency virus type 1 integrase protein.

Authors:  C G Shin; B Taddeo; W A Haseltine; C M Farnet
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  The nuclear localization signal of the matrix protein of human immunodeficiency virus type 1 allows the establishment of infection in macrophages and quiescent T lymphocytes.

Authors:  U von Schwedler; R S Kornbluth; D Trono
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

View more
  7 in total

1.  Revealing domain structure through linker-scanning analysis of the murine leukemia virus (MuLV) RNase H and MuLV and human immunodeficiency virus type 1 integrase proteins.

Authors:  Jennifer Puglia; Tan Wang; Christine Smith-Snyder; Marie Cote; Michael Scher; Joelle N Pelletier; Sinu John; Colleen B Jonsson; Monica J Roth
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  High-throughput, library-based selection of a murine leukemia virus variant to infect nondividing cells.

Authors:  Julie H Yu; David V Schaffer
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Retroviral replicating vectors in cancer.

Authors:  Christopher R Logg; Joan M Robbins; Douglas J Jolly; Harry E Gruber; Noriyuki Kasahara
Journal:  Methods Enzymol       Date:  2012       Impact factor: 1.600

4.  Insertion of a classical nuclear import signal into the matrix domain of the Rous sarcoma virus Gag protein interferes with virus replication.

Authors:  Rachel A Garbitt; Karen R Bone; Leslie J Parent
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  The cell cycle independence of HIV infections is not determined by known karyophilic viral elements.

Authors:  Masahiro Yamashita; Michael Emerman
Journal:  PLoS Pathog       Date:  2005-11-11       Impact factor: 6.823

6.  Molecular mechanisms of retroviral integration site selection.

Authors:  Mamuka Kvaratskhelia; Amit Sharma; Ross C Larue; Erik Serrao; Alan Engelman
Journal:  Nucleic Acids Res       Date:  2014-08-21       Impact factor: 16.971

7.  Altering murine leukemia virus integration through disruption of the integrase and BET protein family interaction.

Authors:  Sriram Aiyer; G V T Swapna; Nirav Malani; James M Aramini; William M Schneider; Matthew R Plumb; Mustafa Ghanem; Ross C Larue; Amit Sharma; Barbara Studamire; Mamuka Kvaratskhelia; Frederic D Bushman; Gaetano T Montelione; Monica J Roth
Journal:  Nucleic Acids Res       Date:  2014-03-12       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.